19:16 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Galapagos reports Phase Ib data for GLPG1972 in OA

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) reported top-line data from a Phase Ib trial in 30 patients ages 50-75 with knee and/or hip osteoarthritis (OA) showing that three dose levels of once-daily oral GLPG1972 for four weeks...
18:01 , Sep 1, 2017 |  BC Week In Review  |  Company News

Servier gets rights to Galapagos' OA candidate

In July, Servier (Neuilly-sur-Seine, France) said it exercised its option for worldwide commercialization rights, excluding the U.S., to GLPG1972 (S201086) from Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG). Galapagos retains U.S. commercialization rights. Galapagos will receive a €6 million...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

Antitope, Rottapharm Madaus deal

Antitope said it completed a research deal with Rottapharm's antibody unit Rottapharm Biotech s.r.l. to profile the immunogenicity of Rottapharm's CRB0017. Under the deal, Antitope applied its EpiScreen and in silico iTope/TCED technologies in...
08:00 , Dec 8, 2011 |  BC Innovations  |  Cover Story

Big MAC attack in osteoarthritis

An international research team has shown that inhibiting the complement system slows disease progression in mice with osteoarthritis, thus pointing to complement inhibitors as potential disease modifiers.1 Although the findings offer companies developing inhibitors of...